The Pharmaceutical Market: Cambodia

The Pharmaceutical Market: Cambodia

Cambodia Pharmaceuticals & Healthcare Report Lacklustre efforts by the government to boost healthcare means that the Cambodia will be the least attractive to pharmaceutical investors as compared to its South East Asian peers as the population are unable to afford new treatments. Over the longer term we expect such trends to change and active participation in the Association of Southeast Asia Nations (ASEAN) Economic Community will boost its attractiveness. Headline Expenditure Projections Pharmaceuticals: KHR718bn (US$178mn) in 2011 to KHR806bn (US$193mn) in 2012; +12.2% in local currency terms and +8.8% in US dollar terms. Growthforecast unchanged from Q312, although we have adjusted the absolute value following reassessment of the market size. Healthcare: KHR2,982bn (US$737mn) in 2011 to KHR3,312bn (US$794mn) in 2012; +11.1% in local currency terms and +7.8% in US dollar terms. Forecast unchanged from Q3 12. MedicalDevices: KHR108bn (US$27mn) in 2011 to KHR118bn (US$28mn) in 2011; +9.8% in local currency terms and +6.6% in US dollar terms. Forecast unchanged from Q3 12. Risk/RewardRating: Cambodia remains last out of the18 key markets in BMI's Q412 Asia Pacific Pharmaceutical Risk/Reward Ratings with a score of 33.5, significantly lower than the regional average of 53.3. Near-term risks includes rampant corruption and poor healthcare provision although its membership in the ASEAN can boost its long-term attractiveness. Competitive Landscape The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors. table Of Contents

bmi Industry View 7

swot 9

industry Forecast 11

pharmaceutical Market Forecast 11 table: Pharmaceutical Sales Indicators, 2009-2017 12

healthcare Market Forecast 13 table: Healthcare Expenditure Indicators, 2009-2017 14 table:...